Psychedelic Drugs Industry

The global psychedelic drugs market size was valued at USD 1,595.5 million in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 12.1% from 2023 to 2030. This anticipated growth is largely driven by the increasing global awareness surrounding the importance of mental health treatment, alongside the rising prevalence of mental health disorders. These factors are expected to significantly influence the expansion of the psychedelic drugs market throughout the forecast period. In addition to these drivers, the growing number of government-led initiatives aimed at promoting mental health awareness and access to mental healthcare services is also expected to contribute to market development. For example, in May 2022, the Mental Health Foundation organized Mental Health Awareness Week to highlight the impact of loneliness on mental well-being and to encourage public engagement on mental health topics.

The outbreak of the COVID-19 pandemic had a notably positive impact on the growth trajectory of the psychedelic drugs market. During the pandemic, lockdowns and restrictions led to a spike in reported cases of anxiety and depression across many regions. According to a report by the World Health Organization, the COVID-19 crisis resulted in a 25% global increase in the prevalence of anxiety and depression, underscoring the urgent need for effective mental health interventions. This dramatic rise in mental health conditions directly contributed to a heightened demand for psychedelic drug therapies. Moreover, the economic disruption caused by the pandemic led to widespread job losses, which further exacerbated depression rates and created additional market demand. As noted in a report from the Center on Budget and Policy Priorities, millions of individuals lost employment during the early stages of the crisis, intensifying the need for mental health support and pharmaceutical solutions.

The consistently rising incidence of mental health disorders remains one of the most influential drivers of the psychedelic drugs market. For example, a report by the Mental Health Foundation highlighted that in 2022/23, high anxiety levels were reported by an average of 37.1% of women and 29.9% of men. Similarly, according to data from Statistics Canada, the percentage of individuals aged 15 years and older diagnosed with generalized anxiety disorder doubled over a ten-year period, increasing from 2.6% in 2012 to 5.2% in 2022. These mental health conditions—including psychosis, panic attacks, anxiety, and depression—often require pharmaceutical treatment involving psychedelic substances. As these disorders continue to become more prevalent, the demand for psychedelic drug therapies is expected to increase accordingly, supporting continued market expansion.

Curious about the Psychedelic Drugs Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Drug Type Insights

On the basis of drug type, the psychedelic drugs market is categorized into several segments: Gamma Hydroxybutyric Acid (GHB), Ketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), and other drug types. Among these, the psilocybin segment held the largest market share in 2022. Psilocybin is a naturally derived psychedelic compound that has shown promise in the treatment of various mental health disorders. The continued increase in product approvals, along with the establishment of specialized research centers focusing on psychedelic medicine, is projected to further support the growth of this segment throughout the forecast period. For instance, in August 2021, the University of Wisconsin–Madison launched a dedicated research center aimed at coordinating education and ongoing research related to psychedelic compounds, demonstrating growing institutional interest in this area of medicine.

Key Companies & Market Share Insights

Prominent players in the market include Jazz Pharmaceuticals, NeonMind BioSciences, Cybin Corp., Pfizer Inc., Numinus, Mind Medicine, PharmaTher Holdings Ltd, NRx Pharmaceuticals Inc., Seelos Therapeutics, Havn Life, Revive Therapeutics, and Usona Institute. These industry leaders remain dedicated to continuous innovation through new product development, strategic M&A activities, and forming key alliances, all aimed at exploring fresh avenues in the market. Some of the instances of such initiatives include:

• In September 2023, Cybin Inc. announced a strategic collaboration with Fluence, a leading organization in psychedelic therapy continuing education. This collaboration is designed to support the scaling of the EMBARK training program for the CYB003 phase 3 trial.
• In October 2022, Numinus Wellness Inc., a prominent mental health care company, initiated a groundbreaking program offering Ketamine for the treatment of chronic and serious medical illnesses. This pioneering program was initially rolled out in Numinus' clinics located in Utah, British Columbia, and Quebec.

Order a free sample PDF of the Psychedelic Drugs Market Intelligence Study, published by Grand View Research.